Generic Semaglutide Timeline
Launched abroad in 2026; US patents run to the early 2030s.
Launched abroad in 2026; US patents run to the early 2030s.
Across the 20 programmes we price, all-in cost runs from $145 a month at the starter dose, with the cheapest first year at about $1,740 (NexLife, $145 a month at a 2.4 mg maintenance dose). Every figure on this page is on that same all-in basis.
All-in monthly cost = medication + any recurring fee, at a named dose, before tax and before prepaid discounts. Captured 2026-08-05. How we verify a price.
All-in monthly cost at 2.4 mg
How to verify this yourself
Regulatory summaries age badly, this one included. FDA's drug compounding pages, its shortage database and its published warning letters are the primary sources, all free and searchable by company name. If this page and the agency disagree, the agency is right and telling us is the fastest way to fix it for everyone.
Proposal, enforcement, or rule
Three different things that coverage routinely conflates. A proposed exclusion from a bulks list is not a rule. A warning letter is about claims rather than a finding of patient harm. Only a final rule changes what is lawful. If a regulatory story is being used to sell you something urgently, the urgency is the marketing.
What it changes for a patient
Rarely the prescription requirement, the pharmacy licensing framework or the clinical review. Usually price, which programmes operate, and what may lawfully be compounded at scale. Do not let supply run to zero, keep your prescriber informed of interruptions, and avoid long prepaid terms with programmes whose pharmacy you cannot identify.
Proposal, enforcement, or final rule
Three different things that coverage routinely conflates. A proposed exclusion from a bulks list is not a rule. A warning letter is a formal statement that specific claims are unlawful, not a finding of patient harm. Only a final rule changes what may lawfully be done.
If a regulatory story is being used to sell you something urgently, the urgency is the marketing. Nothing in this category has ever required a same-day decision from a patient.
How to verify any of this yourself
FDA's drug compounding pages, its shortage database and its published warning letters are the primary sources, all free and searchable by company name. State boards publish their own actions. If this page and the agency disagree, the agency is right and telling us is the fastest way to fix it for everyone.
What regulatory change does and does not touch
It rarely changes the prescription requirement, the pharmacy licensing framework or the clinical review. It routinely changes price, which programmes operate, and what may be compounded at scale. Several large platforms left the compounded market during 2026 for exactly these reasons.
The practical defences are boring: do not let supply run to zero, keep your prescriber informed of interruptions, and avoid long prepaid terms with programmes whose pharmacy you cannot identify.
How this connects to what you will actually pay
Everything in this section resolves to one number: the all-in monthly cost at the dose you end up holding. Across the 20 programmes we price, that runs from $145 at the cheapest tracked route to several times that at the most expensive, for the identical molecule from the same category of licensed pharmacy.
4 of those programmes charge a recurring platform fee on top of medication and 19 hold one price at every strength. Those two facts explain most of the spread between advertised prices and real ones.
What we could verify and what we could not
4 of 32 tracked programmes have a price we read at the provider or manufacturer. The rest carry third-party figures we have not confirmed, or publish nothing we can interpret. Every table on this site marks which is which, and the comparison matrix lets you filter to verified prices only.
Where we have checked a third-party figure against a provider's own page, it has almost always moved — and it has moved upward. Promotional first months, prepaid bundle rates and medication-only figures that exclude memberships are all published as ongoing all-in prices. Assume an unverified figure is optimistic.
The regulatory distinction that sits under all of this
Compounded semaglutide is not FDA-approved. FDA does not review compounded preparations for safety, effectiveness or quality before they are marketed. The active molecule is the same as the branded product; the pre-market review is not, and the assurance comes instead from the pharmacy, the state board that licenses it and, at good operations, batch sterility and potency testing.
That is a legitimate framework rather than a loophole, and it is also why the price is lower. It puts more of the verification burden on the patient, which is the honest trade being made.
How to check this against the primary record
Regulatory summaries age badly, this one included. FDA publishes its compounding pages, its shortage database and its warning letters, all free and searchable by company name. Where this page and the agency disagree, the agency is right.
Three things get conflated in coverage of this area: a proposal, an enforcement action and a final rule. Only the third changes what is lawful.
What it changes for someone paying cash
Rarely the prescription requirement, the licensing framework or the clinical review. Usually price, which programmes operate, and what may lawfully be compounded at scale. Five large programmes stopped selling compounded semaglutide during 2026 and patients generally found out at renewal.
The practical response is unglamorous: do not let supply run to zero, keep a prescriber informed of interruptions, and avoid long prepaid terms with programmes whose pharmacy you cannot identify.
Why regulatory news is used as a sales tool
Because urgency sells. A programme citing a rule change to push you into a twelve-month prepayment is using a genuine regulatory fact to manufacture a deadline that does not apply to you. Read the rule, not the email about the rule.
Reading this against the rest of the decision
This sits inside a decision with three parts: what you pay at the dose you hold, who makes what you are injecting, and what happens if you stop. Most published guidance covers the first and treats the other two as footnotes.
They are not footnotes. A price advantage of a few hundred dollars a year is erased by one interrupted month, and an interruption is a clinical event rather than an inconvenience — semaglutide takes sixteen weeks to re-titrate from the starter dose.
Which is why this section exists separately from the pricing pages, and why the verification steps on it are worth completing even when the programme you are considering is the cheapest on the site.
What to do with this before you enrol
Turn it into two or three questions you can send in an email. Anything here that cannot be converted into a question a programme could answer in writing is context rather than a check, and context does not protect you.
The programmes that answer promptly and specifically are, in our reading of the public record, rarely the ones patients later write about. That is a weak signal rather than evidence, but it costs nothing to collect and it arrives before your money does.
If a programme declines to answer, that is an answer. The market currently offers 20 priced alternatives, the cheapest verified at $145 a month all-in at a maintenance dose.
The failure mode this section guards against
Choosing a programme on a number that describes a different situation than yours. An entry price when you will hold maintenance. A medication figure when a membership applies. A promotional rate when you will renew.
Each error is small alone and they compound in one direction, which is why the cheapest-looking option in most published comparisons is the one most likely to be mis-stated. Priced correctly the cheapest verified route sits at $145 a month all-in at a 2.4 mg maintenance dose.
Why we publish the working rather than a verdict
A single recommendation reads better and acts worse, because it hides the weighting. Two readers with different maintenance doses, different coverage and different tolerance for commitment should not receive the same answer.
So the tables carry the inputs and every ranking states its sort key. Disagree with our weighting and you can take the file and weight it yourself — which is what publishing it is for.
The number most people get wrong
The month-six figure. Almost everyone budgets from the first month, which on semaglutide describes four weeks at 0.25 mg — roughly 1 mg of active drug against the 9.6 mg a maintenance month delivers.
Ten of your first twelve months are spent at or near maintenance. A ranking sorted on the advertised month is sorting on about eight per cent of your year, and on a dose-scaled programme those are different numbers entirely.
Run the first-year calculator at the dose you expect to hold. It takes under a minute and it reorders the market for most people.
What a year of this actually looks like
Four weeks at 0.25 mg, four at 0.5 mg, four at 1 mg, four at 1.7 mg, then 2.4 mg for the remainder. Sixteen weeks of titration if nothing is repeated, and repeats are common rather than exceptional.
Budget two extra months at a lower tier and treat anything better as upside. Fix a weekly injection day, record dose and date, and diary the renewal date if an introductory rate applies — the reversion is where most complaints in this category begin.
How much generic semaglutide timeline should weigh
Less than the dose question and more than the brand. 19 of 20 programmes hold one price from 0.25 mg to 2.4 mg; the rest reprice as you climb. Which group you choose changes a twelve-month total more than almost any other single decision.
That is because semaglutide titrates slowly. Sixteen weeks minimum to a maintenance dose, frequently longer for tolerability, and a dose-scaled programme reprices you at every step of it.
Flat pricing is worst value at the bottom of the ladder and best at the top, which makes it less a lower price than insurance against a decision your prescriber has not made yet.
What a well-run programme publishes
Its price at every strength. Its pharmacy. Its prescriber's licensure. Its cancellation notice period. And which form of the active ingredient it compounds from, because FDA has distinguished semaglutide base from salt forms and linked the salts to safety concerns.
That last one is specific to this molecule and almost never asked. Programmes that answer it precisely are telling you how closely they supervise their supply chain.
Open these rather than taking our word for it. Every one is a regulator, a trial registry, a label, an accreditor or the manufacturer.
Compare every programme on one screen
The matrix carries all-in price at every dose, fee structure, commitment terms, pharmacy disclosure and verification status for every programme we track.